The inhibition of metalloproteinases to treat osteoarthritis: Reality and new perspectives

Expert Opinion on Therapeutic Patents

Volumn 12, Issue 1, 2002, Pages 29-43

  Henrotin, Y ^a   Sanchez, C ^a   Reginster, J Y ^a  

^a CHU SART TILMAN   (Belgium)

Author keywords

Cartilage; Inhibitors; Metalloproteinases; Osteoarthritis

Indexed keywords

1N (4 N BUTOXYBENZENSULFONYL) 2 N HYDROXYCARBOXAMIDO 4 1N (3N ALLYLHYDANTOIN 1N YL)PYRROLIDINE; 1N (4 N BUTOXYBENZENSULFONYL) 2 N HYDROXYCARBOXYAMIDO 4 (MORPHOLIN 1N YL)PYRROLIDINE; 1N (4 N BUTOXYBENZENSULFONYL) 2 N HYDROXYCARBOXYAMIDO 4 1N (3N METHYLHYDANTOIN 1N YL)PYRROLIDINE; 1N (4 N PROPOXYBENZENSULFONYL) 2 N HYDROXYCARBOXYAMIDO 4 (MORPHOLIN 1N YL)PYRROLIDINE; 1N [4 (2 METHOXYETHOXY)BENZENSULFONYL] 2 N HYDROXYCARBOXAMIDO 4 1N (3N METHYLHYDANTOIN 1N YL)PYRROLIDINE; 3 (FORMYL HYDROXYAMINO) 2 (2 METHYL 1 PROPYL) 4 METHYLPENTANOIC ACID [2 METHYL 1 (2 PYRIDYLCARBAMOYL) 1 BUTYL]AMIDE; 4 [[[4 (4 CHLOROPHENOXY)PHENYL]SULFONYL]METHYL]TETRAHYDRO 2H PYRAN 4 CARBOHYDROXAMIC ACID; ANALGESIC AGENT; BATIMASTAT; BENZENESULFONAMIDE DERIVATIVE; CIPEMASTAT; COLLAGENASE 3; CYTOKINE; D 1927; ETANERCEPT; GLUCOSAMINE SULFATE; GW 3333; ILOMASTAT; INFLIXIMAB; INTERSTITIAL COLLAGENASE; MARIMASTAT; MATRIX METALLOPROTEINASE 14; METALLOPROTEINASE INHIBITOR; NEUTROPHIL COLLAGENASE; NONSTEROID ANTIINFLAMMATORY AGENT; PRINOMASTAT; PYRROLIDINE DERIVATIVE; REBIMASTAT; RO 323555; TANOMASTAT; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; CARTILAGE DEGENERATION; CLINICAL STUDY; CONTROLLED STUDY; DRUG MECHANISM; DRUG SELECTIVITY; DRUG STRUCTURE; ENZYME INHIBITION; HUMAN; NONHUMAN; OSTEOARTHRITIS; PATENT; PATHOPHYSIOLOGY; PROTEIN FAMILY; REVIEW;

EID: 0036137433     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.12.1.29     Document Type: Review

References (121)

1. Structure and function of normal human adult articular cartilage
2. Biochemical factors in joint articular tissue degradation
3. The role of the chondrocyte in osteoarthritis
4. Measurement of matrix metalloproteinases (MMPs) and tissue inhibitor of metalloproteinases-1 (TIMP-1) in patients with knee osteoarthritis: Comparison with generalized osteoarthritis
5. Matrix metalloproteinase and proinflammatory cytokine production by chondrocytes of human osteoarthritic cartilage
6. Matrix metalloproteinase-1, -3, -13 and aggrecanase-1 and -2 are differentially expressed in experimental osteoarthritis
7. Expression of vitamin D receptors and matrix metalloproteinases in osteoarthritic cartilage and human articular chondrocytes in vitro
8. Immunohistochemical analysis of several proteolytic enzymes as parameters of cartilage degradation
9. Activation of procollagenases is a key control point in cartilage collagen degradation
10. Stromelysin is an activator of procollagenase: A study with natural and recombinant enzymes
11. Direct activation of human neutrophil procollagenase by recombinant stromelysin
12. Tissue cooperation in a proteolytic cascade activating human intertitial collagenase
13. Further studies on the activation of procollagenase, the latent precursor of bone collagenase: Effects of lysosomal cathepsin B, plasmin and kallikrein, and spontaneous activation
14. Cartilage synthesizes the serine proteinase inhibitor PAI-1: Support for the involvement of serine proteases in cartilage remodeling
15. Plasminogen activators and their inhibitors in synovial fluids from normal, osteoarthritis, and rheumatoid arthritis knees
16. Plasmin, Plasminogen activators and inhibitors in human osteoarthritic cartilage
17. Evidence for metalloproteinases and metalloproteinase inhibitor imbalance in human osteoarthritic cartilage
18. Expression of matrix metalloproteinases in normal and damaged articular cartilage from human knee and ankle joints
19. Aggrecan degradation in human cartilage
20. Enhanced cleavage of type II collagen by collagenases in osteoarthritic articular cartilage
21. Distribution of aggrecanase (ADAMts 4/5) cleavage products in normal and osteoarthritic human cartilage: The influence of age topography and zone of tissue
22. Serum levels of collagenase, stromelysin-1, and TIMP-1
23. Metalloproteinases, tissue inhibitor, and proteoglycan fragments in knee synovial fluid in human osteoarthritis
24. Degradation of type II collagen, but not proteoglycan, correlates with matrix metalloproteinase activity in cartilage explant cultures
25. Matrix metalloproteinases and aggrecanases cleavage aggrecan in different zones of normal cartilage but cofocalize in the development of osteoarthritic lesions in STR/ort mice
26. Excess of metalloproteases over tissue inhibitor of metalloprotease may contribute to cartilage degradation in osteoarthritis and rheumatoid arthritis
27. Localization of matrix metalloproteinase 3 (stromelysin) in osteoarthritic cartilage and synovium
28. Selective enhancement of collagenase-mediated cleavage of resident type II collagen in cultured osteoarthritic cartilage and arrest with a synthetic inhibitor that spares collagenase 1 (matrix metalloproteinase 1)
29. Cloning, expression, and type II collagenolytic activity of matrix metalloproteinase-13 from human osteoarthritic cartilage
30. Synergic induction of matrix metalloproteinase 1 by interleukin-1α and oncostatin M in human chondrocytes involves signal transducer and activator of transcription and activator protein 1 transcription factors via a novel mechanism
31. The new collagenase, collagenase-3, is expressed and synthesized by human chondrocytes but not by synoviocytes: A role in osteoarthritis
32. Collagenase-1 and collagenase-3 synthesis in normal and early experimental osteoarthritic canine cartilage: An immunohistochemical study
33. Differential patterns of response to doxycycline and transforming growth factor β1 in the down-regulation of collagenases in osteoarthritic and normal human chondrocytes
34. Collagenase 3 production by human osteoarthritic chondrocytes in response to growth factors and cytokines is a function of the physiologic state of the cells
35. Interleukin-1 induction of collagenase 3 (matrix metalloproteinase 13) gene expression in chondrocytes requires p38, c-jun n-terminal kinase, and nuclear factor kB
36. The structure of aggrecan fragments in human osteoarthritic synovial fluid: Evidence for the involvement in osteoarthritis of a novel proteinase which cleaves the glu373-ala374 bond of the interglobular domain
37. ADAMTS: A novel family of extracellular matrix proteases
38. Mechanisms involved in cartilage proteoglycan catabolism
39. The thrombospondin motif of aggrecanase 1 (ADAMTS-4) is critical for aggrecan substrate recognition and cleavage
40. Identification of aggrecanase activity in medium of cartilage culture
41. Expression and activity of ADAMTS-5 in synovium
42. The role of ADAM-TS4 (aggrecanase-1) and ADAM-TS5 (aggrecanase-2) in a model of cartilage degradation
43. TIMP-3 is a potent inhibitor of aggrecanase-1 (ADAM-TS4) and aggrecanase-2 (ADAM-TS5)
44. ADAM-TS1 cleaves a cartilage proteoglycan, aggrecan
45. Expression of ADAMTS homologue in articular cartilage
46. Cloning and characterization of ADAMTS11, an aggrecanase from the ADAMTS family
47. Expression of membrane type 1 matrix metalloproteinase in human articular cartilage
48. Membrane type 1 matrix metalloproteinase digest interstitial collagens and other extracellular matrix macromolecules
49. Expression of membrane type 1 matrix metalloproteinase and activation of progelatinase A in human osteoarthritic cartilage
50. Up-regulation of MDC15 (metargidin) messenger RNA in human osteoarthritic cartilage
51. Expression of members of a novel membrane linked metalloproteinase family (ADAM) in human articular chondrocytes
52. A metalloproteinase desintegrin that releases tumour-necrosis factor α from cells
53. TNF-α convertase enzyme from human arthritis-affected cartilage: Isolation of cDNA by differential display, expression of the active enzyme, and regulation of TNF-α
54. ADAM-10 protein is present in human articular cartilage primarily in the membrane form and is upregulated in osteoarthritis and in response to IL-1α in bovine nasal cartilage
55. Biochemical characterization of human collagenase-3
56. A matrix metalloproteinase expressed on the surface of invasive tumour cells
57. Identification of the second membrane-type matrix metalloproteinase (MT-MMP-2) gene from a human placenta cDNA library: MT-MMPs form a unique membrane-type subclass in the MMP family
58. Identification of soluble type of membrane-type matrix metalloproteinases-3 formed by alternatively spliced mRNA
59. Identification and characterization of the fifth membrane-type metalloproteinases MT5-MMP
60. Human MT6-matrix metalloproteinase: Identification, progelatinase A activation and expression in brain tumors
61. Furin-dependent intracellular activation of the human stromelysin-3 zymogen
62. Endogenous activation of latent collagenase by rheumatoid synovial cells: Evidence for a role of plasminogen activator
63. The urokinase-type plasminogen activator system in cancer metastasis: A review
64. Expression of the urokinase-type plasminogen activator receptor in human articular chondrocytes: Association with caveolin and β 1-integrin
65. Antisense oligonucleotides against the urokinase receptor: A therapeutic strategy for of cell invasion in rheumatoid arthritis and cancer
66. Antisense targeting of the urokinase receptor blocks urokinase-dependent proliferation, chemoinvasion, and chemotaxis of human synovial cells and chondrocytes in vitro
67. Direct plasminogen activation at the surface of normal and malignant cells
68. Recombinant human interleukin-1 inhibits plasminogen activator inhibitors-1 (PAI-1) production by human articular cartilage and chondrocytes
69. The relative importance of cysteine peptidases in osteoarthritis
70. Cathepsin B and cysteine protease inhibitors in human OA: Effect of intra-articular steroid injections
71. Differential expression of cathepsins B and L compared with matrix metalloproteinases and their respective inhibitors in rheumatoid arthritis and osteoarthritis
72. Expression of cathepsin K messenger RNA in giants cells and their precursors in human osteoarthritis synovial tissues
73. Stimulation of angiogenesis through cathepsin B inactivation of the tissue inhibitors of matrix metalloproteinases
74. Cathepsin B and its endogenous inhibitor cystatin C in rheumatoid arthritis synovium
75. Human cathepsin B and cysteine proteinases inhibitors (CPIs) in inflammatory and metabolic disease
76. Binding of active (57 Kda) membrane type-1-matrix metalloproteinase (MTI-MMP) to tissue inhibitor of metalloproteinase (TIMP)-2 regulates MT1-MMP processing and pro-MMP-2 activation
77. Paradoxal effects of tissue inhibitor of metalloproteinases 1 gene transfer in collagen-induced arthritis
78. Recommendations for the medical management of osteoarthritis of the hip and knee. 2000 update
79. Recommendations for the registration of drugs used in the treatment of osteoarthritis
80. Long-term effects of glucosamine sulphate on osteoarthritis progression: A randomised, placebo-controlled clinical trial
81. Glucosamine sulfate decreases progression of knee osteoarthritis in a long-term, randomized, placebo-controlled, independent, confirmatory trial
82. Efficacy and safety of diacerein in osteoarthritis of the knee: A double-blind, placebo controlled trial. The diacerein study group
83. Symptoms modifying effect of avocado/soybean unsaponifiables (ASU) in knee osteoarthritis
84. The effects of glucosamine sulfate (GS04) on human chondrocyte gene expression
85. Chondrocyte-mediated catabolism of aggrecan: Aggrecanase-dependent cleavage induced by interleukin-1 and retinoic acid can be inhibited by glucosamine
86. Avocado/soya unsaponifiables enhance the expression of transforming growth factor β1 and β2 in cultured articular chondrocytes
87. Effects of three avocado/soybean unsaponifiable mistures on metalloproteinases, cytokines and prostaglandin E2 production by human articular chondrocytes
88. Long-term effects of avocado/soybean unsaponifiable on human chondrocytes metabolism
89. Rhein, an active metabolite of diacerein, down-regulates the production of pro-matrix metalloproteinases-1, -2, -9 and -13 and upregulates the production of tissue inhibitor of metalloproteinase-1 in cultured rabbit articular
90. Effect of diacetyl rhein on the development of experimental osteoarthritis. A biochemical investigation
91. The effects of orally administrated diacerein on cartilage and subchondral bone in ovine model of osteoarthritis
92. Effects of diacerein on biosynthesis activities of chondrocytes in culture
93. Modification of articular cartilage and subchondral bone pathology in an ovine meniscectomy model of osteoarthritis by avocado and soya unsaponifiables (ASU)
94. Matrix metalloproteinase inhibitors: Applications in oncology
95. Metalloproteinase inhibitors: New opportunities for the treatment of rheumatoid arthritis and osteoarthritis
96. Ongoing trial with matrix metalloproteinase inhibitors
97. The Design, structure, and therapeutic application of matrix metalloproteinase inhibitors
98. Pharmacokinetics, safety, and tolerability of BAY 12-9566 and nonsteroidal anti-inflammatory agents (naproxen, ibuprofen) during coadministration in patients with osteoarthritis
99. Clinical trials of a stromelysin inhibitor. Osteoarthritis, matrix metalloproteinase inhibition, cartilage loss, surrogate markers, and clinical implications
100. Inhibitions of articular cartilage degradation in culture by a novel nonpeptide matrix metalloproteinase inhibitor
101. Inhibition of of articular cartilage degradation in dog and guinea pig models of osteoarthritis by the stromelysin inhibitor, BAY 12-9566
102. Molecular changes in human osteoarthritic cartilage after 3 weeks of oral administration of BAY 12-9566. A novel matrix metalloproteinase inhibitor
103. Disease modification by RS-130,830, a collagenase selective inhibitor in experimental osteoarthritis (OA)
104. RO 32-3555, an orally active collagenase inhibitor, prevents cartilage breakdown in vitro and in vivo
105. Ro 32-3555, an orally active collagenase selective inhibitor, prevents structural damage in the str/ort mouse model of osteoarthritis
106. The tolerability and pharmacokinetics of the cartilage protective agent (RO 32-3555) in healthy male volunteers
107. Roche puts arthritis drug on hold
108. Development of new hydroxamate matrix metalloproteinase inhibitors derived from functionalized 4-aminoprolines
109. A novel snake venom-like protease (SVP) from human arthritis-affected cartilage has properties of TNF-α convertase regulation in arthritis-affected cartilage
110. Cytokine expression in synovial membranes of patients with rheumatoid arthritis and osteoarthritis
111. Metalloproteinases and tumor necrosis factor-α activities in synovial fluids of horse and correlation with articular cartilage alterations
112. Regulation of expression of cytokines and growth factors in osteoarthritic cartilage explants
113. Chondroprotective effect of intraarticular injections of interleukin-1 receptor antagonist in experimental osteoarthritis: Suppression of collagenase expression
114. Role of interleukin-1, tumor necrosis factor alpha, and interleukin-6 in cartilage proteoglycan metabolism and destruction. Effect of in situ blocking in murine antigen-and zymosan-induced arthritis
115. The role of tumour necrosis factor (TNF) in arthritis: Studies in transgenic mice
116. Tumour necrosis factor soluble receptors behave as acute phase reactants following surgery in patients with rheumatoid arthritis, chronic osteomyelitis and osteoarthritis
117. Tumor necrosis factor α can contribute to focal loss of cartilage in osteoarthritis
118. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrasis factor alpha (cA2) versus placebo in rheumatoid arthritis
119. Treatment of rheumatoid arthritis with recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein
120. Inhibition of tumor necrosis factor α (TNFα) production and arthritis in the rat by GW3333, a dual inhibitor of TNFα-converting enzyme and matrix metalloproteinases